Agilent said it will work with Lasergen to build a clinical sequencing workflow based on the smaller firm's Lightning Terminators sequencing chemistry.
LaserGen has named Mimi Healy CEO and to its board of directors. She is taking over from founder Michael Metzker, who developed and patented the company's proprietary Lightning Terminators.
LaserGen has raised $5 million in a Series A financing round, which it will use to demonstrate accurate sequencing of the Escherichia coli genome and to continue developing its next-generation sequencing system.
Last week, the Baylor College of Medicine spinout disclosed that it has teamed up with National Instruments to build and validate a prototype sequencer that uses its "Lightning Terminator" chemistry.
